No registrations found.
ID
NL-OMON29295
Source
NTR
Brief title
DELTa G
Health condition
radndomized placebo-controlled study on a geriatric ward.
Sponsors and support
Primary sponsor
:
trial medication is sponsored by Novartis
Intervention
Outcome measures
Primary outcome
Length of delirium.
Secondary outcome
1. Length of stay in hospital;
2. Severity of delirium;
3. Need of escape medication;
4. Functional status, 3, 6 and 13 weeks after delirium;
5. Cognition.
Background summary
N/A
Study objective
Rivastigmine is as effective as haloperidol in the treatment of a delirium.
Study design
N/A
Intervention
1. Haloperidol;
2. Rivastigmine.
Public
Jeroen Bosch Hospital, Department Geriatrics,
P.O. Box 90153
P.L.J. Dautzenberg
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6998629
p.dautzenberg@jbz.nl
P.O. Box 90153
P.L.J. Dautzenberg
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6998629
p.dautzenberg@jbz.nl
Scientific
Jeroen Bosch Hospital, Department Geriatrics,
P.O. Box 90153
P.L.J. Dautzenberg
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6998629
p.dautzenberg@jbz.nl
P.O. Box 90153
P.L.J. Dautzenberg
Den Bosch 5200 ME
The Netherlands
+31 (0)73 6998629
p.dautzenberg@jbz.nl
Inclusion criteria
Patients on a geriatric ward and delirium.
Exclusion criteria
1. Already use of rivastigmine/donepezil or galantamine;
2. Parkinson(ism).
Design
Study type
:
Interventional
Intervention model
:
Other
Allocation
:
Randomized controlled trial
Masking
:
Double blinded (masking used)
Control
:
Placebo
Recruitment
NL
Recruitment status
:
Recruiting
Start date (anticipated)
:
Enrollment
:
100
Type
:
Anticipated
Positive opinion
Date
:
Application type
:
First submission
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
Register | ID |
---|---|
NTR-new | NL491 |
NTR-old | NTR533 |
Other | : N/A |
ISRCTN | Incomplete data for ISRCTN |
Summary results
N/A